Belinda Cowling (PhD) was a researcher based at the IGBMC, France. Her research focused on the in vivo investigation of the normal role of proteins in skeletal muscle, the pathological mechanisms that occur during muscle disease, and identifying novel therapeutic targets for myopathies.
She completed her PhD in Australia with Prof. Christina Mitchell (Monash University, Australia) in 2008, where she identified a novel regulator of skeletal muscle mass and strength, which is implicated in human disease and therapy. She then moved to the IGBMC, France to complete a postdoc as a member of the team of Dr. Jocelyn Laporte. There she studied the normal biological function of dynamin 2, which is mutated in centronuclear myopathy, as well as the pathological mechanisms leading to disease. She also identified down regulation of this gene as a novel therapeutic target for centronuclear myopathies. In 2014 she was recruited by INSERM as a tenured researcher. She published more than 25 publications in peer-reviewed journals.
Belinda is cofounder of Dynacure.